{
  "type": "analysis_section_rewrite",
  "timestamp": "2025-08-24T00:57:34",
  "processed": false,
  "inputs": {
    "topic_id": "us_inflation",
    "section": "medium",
    "test": "False",
    "run_id": "us_inflation__analysis_run__1755989660",
    "article_ids": "['M2PF568NP', 'FOM34PUWA', 'A7VLN74BK', 'Q7VVGNSQE', 'WISLWAJ15']",
    "selected_articles_count": "5",
    "material_chars": "58341",
    "output_chars": "2472",
    "saved": "True",
    "saved_field": "medium_analysis",
    "status": "success"
  },
  "details": {
    "llm": {
      "model": "openai/gpt-oss-20b",
      "feedback": "**Actionable edit checklist (compact paragraph)**  \n1. **Cite every claim** – add source IDs after each statistic (e.g., “UAS jobs rose 97 % from 712 to 1,400 【FOM34PUWA】”, “BOJ tight labor market fuels wage growth【A7VLN74BK】”, “Russell 2000 valuation discount ≈ 1 σ below S&P 500【Q7VVGNSQE】”, “Dividend yields 1.8 %–6.7 %【WISLWAJ15】”, “Vor Biopharma target $1.85, Sharpe –0.1642 vs peer –0.3372【M2PF568NP】”).  \n2. **Quantify risk and probability** – assign weights (e.g., 60 % base, 25 % upside, 15 % downside) and numeric ranges for key metrics (e.g., UAS salary $105,912, small‑cap earnings improvement 5–10 % CAGR).  \n3. **Structure a scenario map** – lay out three 3–6 month scenarios with clear triggers (BOJ policy statement, Fed rate cut, quarterly UAS employment release, IPO activity rebound, dividend sustainability review) and invalidations (major demand shock, UAS regulatory clampdown, earnings slump, dividend cut).  \n4. **Integrate macro data** – weave inflation, wage growth, and interest‑rate dynamics into the causal chain, showing how BOJ’s stance feeds corporate earnings and equity valuations.  \n5. **Apply first‑principles to fundamentals** – explain Vor Biopharma’s Sharpe ratio as risk‑adjusted return, and dividend stocks’ payout ratios as sustainability metrics.  \n6. **Reconcile conflicts** – note the UAS data gap (“local/state data sparse【FOM34PUWA】”) and flag it as a watch signal.  \n7. **Add watch‑list signals** – list specific dates/periods: BOJ minutes (Q3 2025), Fed decisions (Q4 2025), UAS employment releases (quarterly), small‑cap earnings season (Q1 2026), dividend payout ratio updates (quarterly).  \n8. **Specify path‑dependency** – e.g., if BOJ keeps tight labor market → wage growth → higher earnings → valuation lift; if UAS growth stalls → supply chain slowdown → small‑cap earnings hit.  \n9. **Clarify base‑case outcome** – state expected Russell 2000 move toward pre‑2020 levels, dividend yields holding, UAS employment expanding, and Vor Biopharma’s upside to $1.85 (≈ 100 % from current $0.90).  \n10. **Adjust tone and length** – keep the paragraph concise (≤ 200 words), remove generic phrases (“tight labor market”), and ensure every claim is backed by a source ID.",
      "tokens": {}
    }
  },
  "id": "us_inflation__medium__us_inflation__analysis_run__1755989660"
}